GSK falls Friday, underperforms market
GSK PLC GSK shares inched down 0.34% to £13.30 Friday, on what proved to be an all-around grim trading session for the stock ...
GSK Is Doing The Right Things But Can't Catch A Break - Rating Downgrade
GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.
FierceBiotech3d
GSK pens $45M Relation-ship with AI biotech to identify fibrotic, osteoarthritis targets
GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for ...
MM&M3d
GSK highlights positive Blenrep data from Phase 3 trial at ASH
GSK announces success of their drug Blenrep at reducing the risk of death in patients diagnosed with multiple myeloma.
GSK rises Monday, outperforms market
GSK PLC GSK shares rose 2.90% to £13.83 Monday, on what proved to be an all-around great trading session for the stock market ...
FiercePharma4d
ASH: With survival win against J&J's Darzalex, GSK bolsters case for return of myeloma ADC Blenrep
Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...
STAT4d
GSK myeloma medicine improves survival in trial, another step in the drug’s revival
GSK last month announced that Blenrep had succeeded in improving overall survival in the trial, called DREAMM-7. The detailed ...
FierceBiotech9d
GSK taps Rgenta to develop new RNA-targeting treatments, offering up to $500M per target
Pharma giant GSK is buying into Rgenta Therapeutics’ mission to develop a pipeline of oral RNA-targeting small molecules. | ...
Barclays Remains a Hold on GlaxoSmithKline (GSK)
Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...
Pharmaceutical Technology17h
Risk adjusted net present value: What is the current valuation of GSK’s Linerixibat?
Linerixibat is a small molecule commercialized by GSK, with a leading Phase III program in Pruritus. According to Globaldata, it is involved in 15 clinical trials, of which 12 were completed, and 3 ...